Picture [iito] No Tracking 650x80px
Organisation › Details

Ermium Therapeutics S.A.S.

Ermium Therapeutics was founded in June 2019 by Jean-Philippe Herbeuval, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo. In addition, Ermium Therapeutics won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education. *


Period Start 2019-06-28 established
Products Industry CXCR4 agonist
  Industry 2 drug development
Person Person Crouzet, Joël (Ermium Therapeutics 201909 CEO)
Region Region Paris
  Country France
  Street 16 Boulevard Saint Germain
  City 75005 Paris
    Address record changed: 2019-09-17
Basic data Employees n. a.
    * Document for �About Section�: Domain Therapeutics S.A.. (9/11/19). "Press Release: Domain Therapeutics Invests in Ermium Therapeutics to Develop First-in-class CXCR4 Candidate for Autoimmune Diseases". Strasbourg.
Record changed: 2020-08-04


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Ermium Therapeutics S.A.S.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top